Clearmind Medicine Inc. (Nasdaq: CMND), a trailblazer in the field of psychedelic-derived therapeutics, is set to make a significant impact at the upcoming Psychedelic Medicine – Israel 2024 conference in Tel Aviv from July 28th to 30th. This gathering of the world’s foremost experts in psychedelic medicine will see Clearmind’s CEO, Dr. Adi Zullof-Shani, present pioneering research on the use of 5-Methoxy-2-Aminoindane (MEAI) for regulating binge behaviors.
Innovations in Treating Binge Behaviors and Obesity
Clearmind’s focus is on developing novel therapies to address severe health challenges that are currently underserved, such as addiction and obesity. At the conference, Dr. Zullof-Shani will explore the promising effects of MEAI in regulating binge behaviors related to alcohol consumption. MEAI not only reduces the desire for excessive alcohol intake but also mimics the euphoria associated with alcohol, offering a controlled, slightly tipsy experience without the negative consequences.
Following Dr. Zullof-Shani’s presentation, esteemed researchers from The Hebrew University of Jerusalem, Prof. Joseph Tam and Dr. Saja Baraghithy, will delve into MEAI’s potential in managing diet-induced obesity. Their findings suggest that MEAI significantly curtails weight gain and improves metabolic health in a diet-induced obesity mouse model, offering a groundbreaking approach to obesity management.
Clearmind’s Commitment to Pioneering Research
“We are honored to present our groundbreaking research at the Psychedelic Medicine – Israel 2024 conference,” said Dr. Zullof-Shani. “MEAI has shown remarkable potential in regulating several binge behaviors and treating overweight. We are excited to share these findings with the scientific community and continue our pursuit of novel solutions for major health challenges.”
Conference Highlights
The Psychedelic Medicine – Israel 2024 conference will serve as an interdisciplinary international forum, showcasing basic, translational, and clinical research in psychedelic medicine. Attendees can expect a diverse program including Plenary Lectures, Thematic Symposia, Poster Sessions, Workshops, and Salons aimed at fostering discussions and interactions among participants.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage biotech company that focuses on the discovery, development, and potential commercialization of psychedelic-derived therapeutics for widespread and underserved health problems, including alcohol use disorder. Its robust intellectual property portfolio includes 28 granted patents across 18 patent families. The company is committed to expanding its reach by seeking additional patents and remaining open to acquiring more intellectual property to strengthen its position in the market.
Shares of Clearmind are actively traded on Nasdaq under the ticker symbol “CMND” and on the Frankfurt Stock Exchange under the symbol “CWY0.”
For more details about Clearmind Medicine Inc. and their innovative approach to psychedelic therapeutics, visit their official website at Clearmind Medicine.
This upcoming conference is a testament to Clearmind’s dedication to leading the charge in utilizing psychedelic compounds to forge new paths in medical treatment, potentially transforming the landscape of psychiatric and metabolic health care.
